Clinical Trials Browser

Available × Plasma cell × Clear all

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT05346835 2026-02-13

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Available

Plasma cell

Multiple Myeloma

NCT03123029 2026-01-30

Expanded Access to Venetoclax

Available

LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04771078 2025-12-12

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Available

Plasma cell

Multiple Myeloma

NCT05100134 2025-12-09

Managed Access Programs for LDK378, Ceritinib

Available

LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT03763370 2024-10-15

Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

Available

Plasma cell

Multiple Myeloma

NCT01250808 2010-12-01

Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy

Available

Plasma cell

Multiple Myeloma

Clinical Trials

KEAP

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Expanded Access to Venetoclax

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Managed Access Programs for LDK378, Ceritinib

Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy